MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 128638 | Name: FAPI-74

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP).

Chemical Structure

FAPI-74
FAPI-74
CAS#2374782-76-8

Theoretical Analysis

MedKoo Cat#: 128638

Name: FAPI-74

CAS#: 2374782-76-8

Chemical Formula: C36H49N9O8

Exact Mass: 735.3704

Molecular Weight: 735.84

Elemental Analysis: C, 58.76; H, 6.71; N, 17.13; O, 17.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
FAPI-74; FAPI 74; FAPI74
IUPAC/Chemical Name
(S)-2,2'-(7-(2-(4-(3-((4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)piperazin-1-yl)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid
InChi Key
ZPDBPTLREULTFT-MHZLTWQESA-N
InChi Code
InChI=1S/C36H49N9O8/c37-22-27-3-1-9-45(27)32(46)23-39-36(52)29-6-7-38-31-5-4-28(21-30(29)31)53-20-2-8-40-16-18-44(19-17-40)33(47)24-41-10-12-42(25-34(48)49)14-15-43(13-11-41)26-35(50)51/h4-7,21,27H,1-3,8-20,23-26H2,(H,39,52)(H,48,49)(H,50,51)/t27-/m0/s1
SMILES Code
O=C(C1=CC=NC(C=C2)=C1C=C2OCCCN(CC3)CCN3C(CN(CCN4CC(O)=O)CCN(CC4)CC(O)=O)=O)NCC(N(CCC5)[C@@H]5C#N)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 735.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, Abe K, Miyake T, Shimazu K, Kobayashi S, Kurokawa Y, Eguchi H, Doki Y, Inohara H, Kato H, Mori Y, Cardinale J, Giesel FL. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023 Aug;64(8):1225-1231. doi: 10.2967/jnumed.123.265486. Epub 2023 Jun 2. PMID: 37268427; PMCID: PMC10394310. 2: Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Röhrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C. FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2021 Feb;62(2):201-207. doi: 10.2967/jnumed.120.245084. Epub 2020 Jun 26. PMID: 32591493; PMCID: PMC8679591. 3: Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, Toyoshima A, Nagata K, Haberkorn U, Kratochwil C, Shinohara A, Hatazawa J, Giesel F. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):871-880. doi: 10.1007/s00259-021-05554-2. Epub 2021 Sep 18. PMID: 34537893; PMCID: PMC8803706. 4: Mori Y, Kramer V, Novruzov E, Mamlins E, Röhrich M, Fernández R, Amaral H, Soza-Ried C, Monje B, Sabbagh E, Florenzano M, Giesel FL, Undurraga Á. Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1605-1611. doi: 10.1007/s00259-023-06564-y. Epub 2023 Dec 20. PMID: 38117298; PMCID: PMC11043111. 5: Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liousia M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Puré E, Sellmyer MA. Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF- FAPI-74. Clin Cancer Res. 2022 Dec 15;28(24):5330-5342. doi: 10.1158/1078-0432.CCR-22-1379. PMID: 35972732; PMCID: PMC9771904. 6: Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, Wu H, Zhang J, Chen X, Chen H. Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT. J Nucl Med. 2024 Jan 2;65(1):40-51. doi: 10.2967/jnumed.123.266329. PMID: 37884330. 7: Glatting FM, Hoppner J, Kauczor HU, Huber PE, Kratochwil C, Giesel FL, Haberkorn U, Röhrich M. Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74. Cancers (Basel). 2022 Oct 28;14(21):5301. doi: 10.3390/cancers14215301. PMID: 36358720; PMCID: PMC9656977. 8: Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, Hubert A, Kratochwil C, Giesel FL, Dendl K, Rathke H, Kauczor HU, Huber PE, Haberkorn U, Röhrich M. Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga- FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions. J Nucl Med. 2022 Dec;63(12):1844-1851. doi: 10.2967/jnumed.122.264069. Epub 2022 May 26. PMID: 35618480; PMCID: PMC9730916. 9: Novruzov E, Giesel FL, Mori Y, Choyke PL, Dabir M, Mamlins E, Schmitt D, Antke C, Pinto C, Soza-Ried C, Fernandez R, Amaral H, Kramer V, Badinez L. Head- to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study. Cancers (Basel). 2023 May 17;15(10):2798. doi: 10.3390/cancers15102798. PMID: 37345133; PMCID: PMC10216510. 10: Watabe T, Fukusumi T, Inohara H, Tatsumi M, Naka S, Kamiya T, Kato H, Mori Y, Cardinale J, Giesel FL. Activated fibroblasts in muscle sarcoidosis revealed by [18F]FAPI-74 PET. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3481-3482. doi: 10.1007/s00259-023-06263-8. Epub 2023 Jun 5. PMID: 37272954; PMCID: PMC10541834.